Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There are concerns that the use of renin-angiotensin system (RAS) blockers may increase the risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or progressing to a severe clinical course after infection. This this study aimed to investigate the influence of RAS blockers on the risk and severity of SARS-CoV-2 infection. Methods: We conducted a retrospective cohort study analyzing nationwide claims data of 215,184 adults who underwent SARS-CoV-2 tests in South Korea. The SARS-CoV-2 positive rates and clinical outcomes were evaluated according to the use of RAS blockers in patients with hypertension (n = 64,243). Results: In total, 38,919 patients with hypertension were on RAS blockers. The SARS-CoV-2 positive rates were significantly higher in the RAS blocker group than in the control group after adjustments (adjusted odds ratio [OR], 1.22; 95% confidence interval [CI], 1.10 to 1.36; p < 0.001), and matching by propensity score (adjusted OR, 1.16; 95% CI, 1.03 to 1.32; p = 0.017). Among the 1,609 SARS-CoV-2- positive patients with hypertension, the use of RAS blockers was not associated with poor outcomes, such as mortality (adjusted OR, 0.81; 95% CI, 0.56 to 1.17; p = 0.265), and a composite of admission to the intensive care unit and mortality (adjusted OR, 0.95; 95% CI, 0.73 to 1.22; p = 0.669). Analysis in the propensity scorematched population showed consistent results. Conclusions: In this Korean nationwide claims dataset, the use of RAS blockers was associated with a higher risk to SARS-CoV-2 infection but not with higher mortality or other severe clinical courses.
Abstract
Background/Aims: There are concerns that the use of renin-angiotensin system (RAS) blockers may increase the risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or progressing to a severe clinical course after infection. This this study aimed to investigate the influence of RAS blockers on the risk and severity of SARS-CoV-2 infection. Methods: We conducted a retrospective cohort study analyzing nationwide claims data of 215,184 adults who underwent SARS-CoV-2 tests in South Korea. The SARS-CoV-2 positive rates and clinical outcomes were evaluated according to the use of RAS blockers in patients with hypertension (n = 64,243). Results: In total, 38,919 patients with hypertension were on RAS blockers. The SARS-CoV-2 positive rates were significantly higher in the RAS blocker group than in the control group after adjustments (adjusted odds ratio [OR], 1.22; 95% confidence interval [CI], 1.10 to 1.36; p < 0.001), and matching by propensity score (adjusted OR, 1.16; 95% CI, 1.03 to 1.32; p = 0.017). Among the 1,609 SARS-CoV-2- positive patients with hypertension, the use of RAS blockers was not associated with poor outcomes, such as mortality (adjusted OR, 0.81; 95% CI, 0.56 to 1.17; p = 0.265), and a composite of admission to the intensive care unit and mortality (adjusted OR, 0.95; 95% CI, 0.73 to 1.22; p = 0.669). Analysis in the propensity scorematched population showed consistent results. Conclusions: In this Korean nationwide claims dataset, the use of RAS blockers was associated with a higher risk to SARS-CoV-2 infection but not with higher mortality or other severe clinical courses.
참고문헌 (25)
- Yang J, "Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2 : a systematic review and meta-analysis", Int J Infect Dis, 94, pp.91~95 (2020)
- Hoffmann M, "SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
- Zheng YY, "COVID-19 and the cardiovascular system", Nat Rev Cardiol, 17, pp.259~260 (2020)
- Fang L, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", Lancet Respir Med, 8, pp.e21~ (2020)
- Diaz JH, "Hypothesis : angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19", J Travel Med, 27, pp.taaa041~ (2020)
- Patel AB, "COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:what is the evidence?", JAMA, 323, pp.1769~1770 (2020)
- Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
- Li J, "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019(COVID-19)infection in Wuhan, China", JAMA Cardiol, 5, pp.1~6 (2020)
- Reynolds HR, "Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19", N Engl J Med, 382, pp.2441~2448 (2020)
- de Abajo FJ, "Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital : a case-population study", Lancet, 395, pp.1705~1714 (2020)
- Guo J, "Coronavirus disease 2019(COVID-19)and cardiovascular disease : a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors", angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, 2020, pp.9, e016219~
- Ferrario CM, "Effects of renin-angiotensin system blockade on renal angiotensin-(1-7)forming enzymes and receptors", Kidney Int, 68, pp.2189~2196 (2005)
- Ocaranza MP, "Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat", Hypertension, 48, pp.572~578 (2006)
- Han SX, "Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats : possible involvement of angiotensin-converting enzyme-2", Toxicol Appl Pharmacol, 245, pp.100~107 (2010)
- Sriram K, "Risks of ACE inhibitor and ARB usage in COVID-19 : evaluating the evidence", Clin Pharmacol Ther, 108, pp.236~241 (2020)
- Mancia G, "Renin-angiotensin-aldosterone system blockers and the risk of Covid-19", N Engl J Med, 382, pp.2431~2440 (2020)
- Mackey K, "Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults : a living systematic review", Ann Intern Med, 173, pp.195~203 (2020)
- Park S, "Information technology-based tracing strategy in response to COVID-19 in South Korea : privacy controversies", JAMA, 323, pp.2129~2130 (2020)
- Onder G, "Case-fatality rate and characteristics of patients dying in relation to COVID-19in Italy", JAMA, 323, pp.1775~1776 (2020)
- Dyer O, "Covid-19: US testing ramps up as early response draws harsh criticism", BMJ, 368, pp.m1167~ (2020)
- Kim Jaiyong, "Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service", Journal of Korean Medical Science, 35(25), pp.1~12 (2020), 대한의학회[DOI]
- Bruine de Bruin W, "Relationships between initial COVID-19 risk perceptions and protective health behaviors : a national survey", Am J Prev Med, 59, pp.157~167 (2020)
- Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
- Gu H, "Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus", Sci Rep, 6, pp.19840~ (2016)
- Bavishi C, "Coronavirus disease 2019(COVID-19)infection and renin angiotensin system blockers", JAMA Cardiol, 5, pp.745~747 (2020)